1
|
Guedea F, Biete A, Ojeda B, Alonso C, Craven-Bartle J. Inflammatory Component: A Worsening Factor in Locally Advanced Breast Cancer Treated by Radiotherapy and Systemic Therapy. TUMORI JOURNAL 2018. [DOI: 10.1177/030089169107700408] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Locally advanced and inflammatory carcinomas of the breast are two distinct entities with clear differential clinical criteria. We described a particular type of locally advanced breast cancer which, during its evolution, developed inflammatory characteristics limited to a small area of the skin. It, therefore, did not meet the common diagnostic criteria of inflammatory carcinoma. In our series, studied from December 1977 to January 1987, we treated 59 cases of locally advanced breast cancer and 105 cases of locally advanced breast cancer with an inflammatory component. The actuarial overall survival was 53.3 % at 5 years and 38.4 % at 7 years. Differences were observed when the two tumor types were compared. Specifically, locally advanced breast cancer with an inflammatory component had a worse prognosis, poorer survival and poorer disease-free rates than locally advanced breast cancer.
Collapse
Affiliation(s)
- Fernando Guedea
- Department of Radiation Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Albert Biete
- Department of Radiation Oncology, Hospital Clinic Provincial, Barcelona, Spain
| | - Belen Ojeda
- Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Carmen Alonso
- Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Jordi Craven-Bartle
- Department of Radiation Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| |
Collapse
|
2
|
Gülben K, Berberoğlu U, Cengiz A, Altınyollar H. Prognostic Factors Affecting Locoregional Recurrence in Patients with Stage IIIB Noninflammatory Breast Cancer. World J Surg 2007; 31:1724-1730. [PMID: 17629742 DOI: 10.1007/s00268-007-9139-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
BACKGROUND The aim of the present study was to identify the clinicopathological factors affecting locoregional recurrence (LRR) in patients with clinical stage IIIB noninflammatory breast cancer (NIBC). METHODS The records of 120 stage IIIB NIBC patients treated with neoadjuvant chemotherapy (NAC) and then modified radical mastectomy followed by radiotherapy were evaluated. In this retrospective cohort, the effects of age, menopausal status, clinical tumor size, clinical response to NAC, pathological axillary status, number of positive axillary lymph nodes, pathological response to NAC, grade, lymphovascular invasion, estrogen receptor status, progesterone receptor status, Her-2-neu status, and p53 status on LRR were evaluated by univariate and multivariate analyses. RESULTS The clinical response rate of 120 patients was 79.2% (17.5% complete and 61.7% partial), with a complete pathological response rate of 12.5%. The median follow-up was 28 months (range: 10-74 months). The LRR rate was 13.3%. Based on the univariate analysis, the clinical tumor size, clinical response rate, pathological axillary status, four or more positive axillary lymph nodes, lymphovascular invasion, and estrogen receptor status were factors that significantly affected LRR. In the multivariate analysis, however, only the clinical response rate and the number of positive axillary lymph nodes were found to be statistically significant independent factors. CONCLUSIONS Effective local control of disease can be achieved in patients with stage IIIB NIBC using a combination of NAC, surgery, and radiotherapy. However, a worse clinical response after chemotherapy and four or more positive axillary lymph nodes affect LRR negatively in these patients.
Collapse
Affiliation(s)
- Kaptan Gülben
- Department of Surgery, Ankara Oncology Training and Research Hospital, Urankent sitesi, C-9 block, No:33, 06200, Demetevler, 06200, Ankara, Turkey.
| | - Uğur Berberoğlu
- Department of Surgery, Ankara Oncology Training and Research Hospital, Urankent sitesi, C-9 block, No:33, 06200, Demetevler, 06200, Ankara, Turkey
| | - Aziz Cengiz
- Department of Surgery, Ankara Oncology Training and Research Hospital, Urankent sitesi, C-9 block, No:33, 06200, Demetevler, 06200, Ankara, Turkey
| | - Hüseyin Altınyollar
- Department of Surgery, Ankara Oncology Training and Research Hospital, Urankent sitesi, C-9 block, No:33, 06200, Demetevler, 06200, Ankara, Turkey
| |
Collapse
|
3
|
Elliott KS, Borowsky ME, Bakdounes K, Huang J, Abulafia O, Lee YC. Malignant thymoma metastatic to the pelvis: a rare case and considerations for management. Gynecol Oncol 2005; 99:228-31. [PMID: 16055177 DOI: 10.1016/j.ygyno.2005.06.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2005] [Revised: 05/12/2005] [Accepted: 06/01/2005] [Indexed: 11/18/2022]
Abstract
BACKGROUND Thymoma is the most common tumor of the anterior mediastinum. Due to its relative rarity, its inconsistent clinical course and its frequent proximity to vital thoracic structures, management of this generally indolent tumor varies considerably. We present an unusual case of recurrent thymoma metastatic to the pelvis and review treatment experience employing surgical, radiotherapeutic and medical modalities. CASE REPORT The present case is that of a 46-year-old woman with recurrent thymoma metastatic to a distal pelvic lymph node. Resection of the pelvic recurrence followed many years of local and systemic treatment for her thoracic primary tumor. Her case is unique for its involvement of pelvic anatomy and her clinical course marked by treatment-related congestive heart failure. CONCLUSION While the indolent clinical course of thyomoma frequently necessitates re-treatment and multi-modality therapy in patients suffering recurrences, treatment selection must take into account potential long-term morbidity and attendant quality of life. When anatomically and technically feasible, resection of recurrent disease should be considered in attempts to avoid potential cumulative and long-term toxicity resultant from radiotherapy and chemotherapy.
Collapse
Affiliation(s)
- Kevin S Elliott
- Department of Obstetrics and Gynecology, State University of New York, Downstate Medical Center, 450 Clarkson Avenue, Box #24, Brooklyn, NY 11203, USA.
| | | | | | | | | | | |
Collapse
|
4
|
McIntosh SA, Ogston KN, Payne S, Miller ID, Sarkar TK, Hutcheon AW, Heys SD. Local recurrence in patients with large and locally advanced breast cancer treated with primary chemotherapy. Am J Surg 2003; 185:525-31. [PMID: 12781879 DOI: 10.1016/s0002-9610(03)00078-3] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
BACKGROUND Primary chemotherapy is being given in the treatment of large and locally advanced breast cancers, but a major concern is local relapse after therapy. This paper has examined patients treated with primary chemotherapy and surgery (either breast-conserving surgery or mastectomy) and has examined the role of factors which may indicate those patients who are subsequently more likely to experience local recurrence of disease. METHODS A consecutive series of 173 women, with data available for 166 of these, presenting with large and locally advanced breast cancer (T2>/=4 cm, T3, T4, or N2) were treated with primary chemotherapy comprising cyclophosphamide, vincristine, doxorubicin, and prednisolone and then surgery (either conservation or mastectomy with axillary surgery) followed by radiotherapy were examined. RESULTS The clinical response rate of these patients was 75% (21% complete and 54% partial), with a complete pathological response rate of 15%. A total of 10 patients (6%) experienced local disease relapse, and the median time to relapse was 14 months (ranging from 3 to 40). The median survival in this group was 27 months (ranging from 13 to 78). In patients having breast conservation surgery, local recurrence occurred in 2%, and in those undergoing mastectomy 7% experience local relapse of disease. Factors predicting patients most likely to experience local recurrence were poor clinical response and residual axillary nodal disease after chemotherapy. CONCLUSIONS Excellent local control of disease can be achieved in patients with large and locally advanced breast cancers using a combination of primary chemotherapy, surgery and radiotherapy. However, the presence of residual tumor in the axillary lymph nodes after chemotherapy is a predictor of local recurrence and patients with a better clinical response were also less likely to experience local disease recurrence. The size and degree of pathological response did not predict patients most likely to experience recurrence of disease.
Collapse
Affiliation(s)
- Stuart A McIntosh
- Aberdeen Breast Unit, Ward 34, Aberdeen Royal Infirmary and University of Aberdeen, Foresterhill, AB25 2ZN, Aberdeen, Scotland, United Kingdom
| | | | | | | | | | | | | |
Collapse
|
5
|
Abstract
The diagnosis and treatment of breast cancer have changed in response to not only new technologies but also cultural and social aspects of the disease. While breast-conserving surgery and adjuvant therapy are the preferred treatments for many breast cancers, neoadjuvant therapy is often used in advanced disease. In this review we examine the treatment options that are influenced by pathologic and clinical factors. Invasive breast cancer is a potentially curable disease if it is regarded and managed by a multidisciplinary approach from the outset.
Collapse
Affiliation(s)
- Atilla Soran
- University of Pittsburgh Cancer Institute/Magee-Womens Hospital, Pittsburgh, Pennsylvania
| | | |
Collapse
|
6
|
Stemmer SM, Pfeffer MR, Rizel S, Hardan I, Goffman J, Gezin A, Neumann A, Kitsios P, Alezra D, Brenner HJ. Feasibility and low toxicity of early radiotherapy after high-dose chemotherapy and autologous stem cell transplantation for patients with high-risk Stage II-III and locally advanced breast carcinoma. Cancer 2001. [DOI: 10.1002/1097-0142(20010601)91:11<1983::aid-cncr1223>3.0.co;2-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
7
|
Bott-Kothari T, Aron BS, Bejarano P. Malignant thymoma with metastases to the gastrointestinal tract and ovary: a case report and literature review. Am J Clin Oncol 2000; 23:140-2. [PMID: 10776973 DOI: 10.1097/00000421-200004000-00007] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
This is the first clinical case report of a thoracic invasive thymoma metastatic to the ovary with disease noted in the entire abdomen including the pelvis 5 1/2 years after initial diagnosis. The involved areas of metastases include the distal ileum, peritoneal and serosal surfaces (including the surface of the distal colon, bladder, and pelvis), and the surface of the right ovary. The patient survived 13 years after her initial diagnosis and 7 1/2 years after discovery of her metastases. Thymomas are rare tumors but comprise the most common primary tumor of the anterior mediastinum. Extrathoracic metastases of malignant thymomas are also rare, and the literature reports that the most common sites for metastases are the liver, lung, lymph nodes, and bone. Extrathoracic disease is associated with a poor prognosis. The average time of survival after the diagnosis of metastases is 1.5 years.
Collapse
Affiliation(s)
- T Bott-Kothari
- Department of Radiation Oncology, Barrett Cancer Center, University of Cincinnati, Ohio 45219-0757, USA
| | | | | |
Collapse
|
8
|
Abstract
The multidisciplinary management of patients with locally advanced breast cancer (LABC) has evolved over the last three decades. The introduction of chemotherapy (CT) and endocrine therapy in conjunction with surgery and radiation therapy (XRT) have changed the natural history of this disease. The authors discuss the role of the taxanes, novel endocrine therapy, and high-dose CT programs in the management of LABC. Indications for breast-conserving surgery are presented. The role of prognostic and predictive tumor markers in LABC is discussed.
Collapse
Affiliation(s)
- F J Esteva
- Department of Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, USA
| | | |
Collapse
|
9
|
Eltahir A, Heys SD, Hutcheon AW, Sarkar TK, Smith I, Walker LG, Ah-See AK, Eremin O. Treatment of large and locally advanced breast cancers using neoadjuvant chemotherapy. Am J Surg 1998; 175:127-32. [PMID: 9515529 DOI: 10.1016/s0002-9610(97)00279-1] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
BACKGROUND Neoadjuvant (primary) chemotherapy is being used increasingly in the treatment of patients with large and locally advanced breast cancer with the aim of reducing the size of the primary tumor and eliminating micrometastatic disease. Response rates to, compliance with, and survival of patients following neoadjuvant chemotherapy have been variable. We report the results of a consecutive series of 77 patients with breast cancer who received neoadjuvant chemotherapy. METHODS Seventy-seven patients with locally advanced breast cancers were treated with multimodality therapy comprising up to six cycles of chemotherapy (cyclophosphamide, vincristine, doxorubicin, and prednisolone), radiotherapy, and then surgery. The median follow-up was 54 months. Clinical response rates to therapy and overall survival have been documented. In addition, prognostic factors for survival were identified using the Cox proportional hazards model. RESULTS The overall objective response rate of the primary tumor to chemotherapy alone was 87% (25% complete and 62% partial responses, UICC criteria). Following radiotherapy the response rate was 90% (52% complete and 38% partial responses). The overall 5-year survival for all patients was 0.48. However, the probability of survival at 5 years was 0.74 in those with a complete response, and 0.36 if there was a partial clinical response, but no patients who had either stasis of disease or progression survived for 5 years. Independent predictors of better survival that were identified were a complete histopathological response after chemotherapy and radiotherapy, a complete clinical response to chemotherapy, and five or six cycles of chemotherapy versus four or less. CONCLUSIONS Neoadjuvant chemotherapy in patients with large and locally advanced breast cancers can result in satisfactory local control and overall survival rates, especially in patients with a complete clinical or histopathological response after treatment.
Collapse
Affiliation(s)
- A Eltahir
- Department of Surgery, University of Aberdeen, Scotland, United Kingdom
| | | | | | | | | | | | | | | |
Collapse
|
10
|
HjiYiannakis P, Yarnold JR. Mixing anthracyclines and radiotherapy in early breast cancer: how safe is it? Eur J Cancer 1996; 32A:2374-7. [PMID: 9038631 DOI: 10.1016/s0959-8049(97)80001-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- P HjiYiannakis
- Department of Radiotherapy and Oncology, Royal Marsden NHS Trust, Sutton, Surrey, U.K
| | | |
Collapse
|
11
|
HjiYiannakis P, Yarnold JR. Mixing anthracyclines and radiotherapy in early breast cancer: how safe is it? Eur J Cancer 1996; 32A:1845-8. [PMID: 8943665 DOI: 10.1016/0959-8049(96)00208-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- P HjiYiannakis
- Department of Radiotherapy and Oncology, Royal Marsden NHS Trust, Sutton, Surrey, UK
| | | |
Collapse
|
12
|
Abstract
Inflammatory breast cancer is an aggressive subtype of invasive breast cancer. Early attempts to control the disease with local treatment modalities alone had a minimal impact on survival. More recently, multimodality treatment approaches that integrate systemic chemotherapy, surgery, and radiotherapy have resulted in improved local disease control and prolonged survival. Better systemic therapies need to be developed since metastatic disease develops in the majority of patients.
Collapse
Affiliation(s)
- W J Gradishar
- Department of Medicine, Robert H. Lurie Cancer Center, Northwestern University Medical School, Chicago, Illinois, USA
| |
Collapse
|
13
|
Styblo TM, Lewis MM, Carlson GW, Murray DR, Wood WC, Lawson D, Landry J, Hughes L, Nahai F, Bostwick J. Immediate breast reconstruction for stage III breast cancer using transverse rectus abdominis musculocutaneous (TRAM) flap. Ann Surg Oncol 1996; 3:375-80. [PMID: 8790850 DOI: 10.1007/bf02305667] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
BACKGROUND The management of state III breast cancer is challenging; it often includes multimodal treatment with systemic therapy and/or radiation therapy and surgery. Immediate breast reconstruction has not traditionally been performed in these patients. We review the results of immediate transverse rectus abdominis musculocutaneous (TRAM) flap in 21 patients treated for stage III breast cancer. METHODS Data have been collected retrospectively on 21 patients diagnosed with stage III breast cancer between 1987 and 1994. All patients had mastectomy and immediate TRAM reconstruction. Thirteen patients received primary systemic therapy, 10 patients received postoperative consolidation radiotherapy to the operative site, and 3 patients received preoperative radiation. RESULTS Mean follow-up for the group was 26 months. Two patients died with disseminated disease: neither of them developed local disease recurrence in the operative site; 82% of the patients followed for at least two years are free of disease. Sixty-two percent of the patients received preoperative chemotherapy, the remaining patients received postoperative multiagent chemotherapy and/or radiation therapy. Two of the patients received autologous bone marrow transplants after their adjuvant therapy. Ten patients had postoperative radiotherapy for consolidation; three patients received preoperative radiation. CONCLUSIONS Immediate TRAM reconstruction for stage III breast cancer is not associated with a delay in adjuvant therapy or an increased risk of local relapse. It facilitates wide resection of involved skin without skin grafting. Radiation therapy can be delivered to the reconstructed breast when indicated without difficulty. Breast reconstruction facilitates surgical resection of stage III breast cancer with primary closure and should be considered if the patient desires immediate breast reconstruction.
Collapse
Affiliation(s)
- T M Styblo
- Department of Pathology, Emory University, Atlanta, Georgia, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Pisansky TM, Loprinzi CL, Cha SS, Fitzgibbons RJ, Grant CS, Hass AC, Reuter NF, Wold LE, Ingle JN, Kardinal CG. A pilot evaluation of alternating preoperative chemotherapy in the management of patients with locoregionally advanced breast carcinoma. Cancer 1996; 77:2520-8. [PMID: 8640701 DOI: 10.1002/(sici)1097-0142(19960615)77:12<2520::aid-cncr15>3.0.co;2-u] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
BACKGROUND This prospective trial was conducted to evaluate the outcome of patients treated with preoperative and post operative chemotherapy, mastectomy, and irradiation for locoregionally advanced breast carcinoma. METHODS Between June 1986 and September 1990, 71 patients received 2 cycles of doxorubicin that alternated with 2 cycles of cyclophosphamide, methotrexate, and 5-fluorouracil prior to mastectomy; irradiation was administered when the tumor was not amenable to surgical resection. Additional chemotherapy and tamoxifen, in hormone receptor-positive tumors, was used after mastectomy. Post-operative irradiation was given on a selective basis for patients at high risk for locoregional disease recurrence. RESULTS Although 5 patients (7%) had disease progression, clinical partial or complete tumor response to preoperative chemotherapy was noted in 46 patients (65%). Sixty-eight patients (96%) underwent mastectomy. With a median follow-up of 52 months, the relapse-free and overall survival rates at 5 years were 42% and 57% respectively. Locoregional tumor recurrence occurred in 14 patients (20%), and 28 patients (39%) developed metastatic disease. Menopausal status, clinical presentation (noninflammatory vs. inflammatory), and American Joint Committee on Cancer clinical stage were independent covariates associated with patient outcome. CONCLUSIONS Preoperative alternating chemotherapy, with the selective use of irradiation, resulted in significant locoregional disease regression and the successful integration of mastectomy into the therapeutic strategy. Locoregional tumor control and relapse-free and overall survival estimates for the approach described herein compared favorably with other comtemporary reports for this condition.
Collapse
Affiliation(s)
- T M Pisansky
- Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Hunt KK, Ames FC, Singletary SE, Buzdar AU, Hortobagyi GN. Locally advanced noninflammatory breast cancer. Surg Clin North Am 1996; 76:393-410. [PMID: 8610271 DOI: 10.1016/s0039-6109(05)70446-1] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Treatment of locally advanced noninflammatory breast cancer has changed markedly over the past 50 years. Haagensen's description of the clinical signs that define inoperable and operable tumors was the first realization that radical surgery alone could not cure the majority of women with locally advanced disease. Studies of the use of local therapy alone (surgery or radiation therapy) confirmed that most patients developed both distant metastatic disease and a high rate of local-regional failure. Combination surgery and radiation therapy regimens improved local control but did not influence long-term survival. The advent of successful multimodal regimens incorporating systemic treatment (chemotherapy or chemohormonal therapy) as well as local therapy (surgery and radiation) has significantly improved disease-free and overall survival as well as local-regional control. The benefits of neoadjuvant and adjuvant chemotherapy regimens have been debated. Neoadjuvant therapy allows clinical and pathologic assessment of tumor response to the chemotherapy regimen. In addition, local-regional control seems to be improved, and reductions in the size of the primary tumor allow breast-preserving procedures, even in patients initially not believed to be candidates for resection. Longer follow-up of these conservatively treated patients will be needed, however, to determine whether local-regional control is preserved.
Collapse
Affiliation(s)
- K K Hunt
- Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
| | | | | | | | | |
Collapse
|
16
|
Abstract
Multimodal therapy with induction chemotherapy has improved significantly local disease control and overall survival in patients with IBC. This is now considered standard therapy for patients with this disease. Although survival has been improved, well over 50% of these patients will succumb to this disease. Ongoing and future investigations may better define the optimal approach for local control, the optimal duration of maintenance chemotherapy, and the possible role of biologic response modifiers and growth factors in further improving the outcome for patients with this disease.
Collapse
Affiliation(s)
- M J Lopez
- Department of Surgery, Tufts University School of Medicine, Boston, Massachusetts, USA
| | | |
Collapse
|
17
|
Abstract
Inflammatory breast cancer (IBC) is a rare subtype of breast cancer traditionally associated with an extremely poor prognosis. The appearance of the effected breast can be misleading, with the incorrect diagnosis of an infective process, rather than a malignant disease, further delaying treatment. Compared with the results achieved by monotherapy with either surgery, radiotherapy or chemotherapy; multimodality treatments have achieved significant improvements in both disease-free and overall survival. The purpose of this article is to provide a comprehensive review of the current literature and highlight those areas where potential advances in the overall management of IBC have been made.
Collapse
|
18
|
Lewis WG, Walker VA, Ali HH, Sainsbury JR. Intra-arterial chemotherapy in patients with breast cancer: a feasibility study. Br J Cancer 1995; 71:605-9. [PMID: 7880745 PMCID: PMC2033640 DOI: 10.1038/bjc.1995.117] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
The aim of this study was to assess the practicality of treating patients with various stages of breast cancer by means of regional (intra-arterial) chemotherapy. Three groups of patients received a median of four (range 2-4) cycles of combination chemotherapy: group I operable primary (n = 10); group II, locally advanced disease (n = 20); group III, recurrent locoregional disease (n = 22). The response rates (complete response, partial response and mixed response) in these groups of patients were 100% in groups I and II and 86% in group III. Morbidity included drug streaming and dysaesthesia in the hand. Patients in groups I and II had their tumours downstaged, allowing surgery to be performed. Local control was also achieved in group III when other treatment modalities had failed.
Collapse
Affiliation(s)
- W G Lewis
- Department of Surgery, Huddersfield Royal Infirmary, UK
| | | | | | | |
Collapse
|
19
|
|
20
|
Abstract
Combined modality therapy has become the treatment of choice for patients with primary breast cancer, including those with locally advanced breast cancer. Primary or induction chemotherapy, followed by surgery or radiation therapy or both, and adjuvant systemic therapy is a generally accepted strategy. Most tumors respond with a more than 50% decrease in tumor size, and approximately 70% of patients experience down-staging through primary chemotherapy. Breast conservation is possible for many patients with locally advanced breast cancer, and almost all patients initially are rendered disease free. Primary chemotherapy should be the initial choice of treatment for patients with locally advanced tumors, but it is unclear what the optimal sequence of subsequent therapies should be, or whether one or two local treatment modalities are necessary. The most dramatic example of the efficacy of these regimens was demonstrated in patients with inflammatory breast cancer. Previously a universally fatal condition, the natural history of this disease has been changed dramatically by the introduction of these combined modality therapies. Five-year survival rates of 35-60% commonly are reported, and it is likely that about one third of patients with this highly aggressive form of disease will survive beyond 10 years without recurrence. Combined modality therapy that includes primary chemotherapy provides appropriate local control, the possibility of breast conservation therapy, and, probably, an increased survival rate, at least for some subsets of patients with locally advanced breast cancer. The use of similar treatment strategies for early breast cancer is currently under evaluation. Hormone therapy and combination chemotherapy represent the main treatment approaches to metastatic breast cancer. Radiotherapy is also a useful palliative tool, especially for control of painful bone metastases and central nervous system involvement. Patient and tumor characteristics help in the optimal selection of systemic therapy. Palliative therapy for symptomatic control and prolongation of life also preserves a good quality of life. Dose-intensive chemotherapy is being evaluated as a treatment to increase complete response rates and cause remission consolidation. Clinical trials on several new and effective cytotoxic agents, as well as new hormonal compounds, are being completed and are showing encouraging preliminary results.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
Affiliation(s)
- G N Hortobagyi
- Department of Breast and Gynecologic Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston 77030
| |
Collapse
|
21
|
Abstract
The management of locally advanced breast cancer with single modality therapy has been associated with a high rate of systemic failure. A multimodality treatment strategy that includes induction cytotoxic chemotherapy, surgery, radiation therapy, and, possibly, hormonal ablation therapy is the current preferred management approach. As our knowledge and understanding of the mechanisms involved in mitogenic signal transduction improve, it is likely that less toxic, more efficacious agents will emerge.
Collapse
Affiliation(s)
- P I Borgen
- Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021
| |
Collapse
|
22
|
Sanchez-Forgach ER, Mamounas EP, Warneke J, Driscoll D, Blumenson LE, Tsangaris TN. Factors affecting outcome in locally advanced breast cancer. Surg Oncol 1992; 1:347-55. [PMID: 1341270 DOI: 10.1016/0960-7404(92)90035-j] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Patients presenting with locally advanced breast cancer (LABC) constitute a diverse group for which a variety of treatment modalities have been instituted. To assess which factors have a direct impact on outcome, we reviewed the medical records of 104 patients diagnosed with stage IIIA, stage IIIB and T3N0M0 breast carcinoma. When considered individually (univariate analysis), clinical stage, pathological stage, oestrogen receptor status and type of therapy were significant predictors for disease-free survival (DFS) and overall survival (OS). However, in a multivariate analysis, only clinical stage was a significant predictor for both DFS and OS, while ER status was a significant predictor for OS. There was a high degree of correlation between clinical and pathological staging. Nearly two-thirds of the patients developed a recurrence by 5 years. Loco-regional recurrence was the site of first recurrence in one-third of the patients by 5 years. The prognosis for patients presenting with LABC is poor, and they should be treated aggressively with loco-regional and systemic multimodality therapy. Although groups of patients with improved outcome could be identified by clinical or pathological staging, no group demonstrated an outcome good enough to be spared from multimodality therapy.
Collapse
Affiliation(s)
- E R Sanchez-Forgach
- Department of Surgical Oncology, Rosewell Park Cancer Institute, Buffalo, New York 14263
| | | | | | | | | | | |
Collapse
|
23
|
Rodger A, Jack WJ, Hardman PD, Kerr GR, Chetty U, Leonard RC. Locally advanced breast cancer: report of phase II study and subsequent phase III trial. Br J Cancer 1992; 65:761-5. [PMID: 1586604 PMCID: PMC1977400 DOI: 10.1038/bjc.1992.160] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Twenty-four evaluable patients with stage T4 breast cancer were entered into a phase II study and received chemotherapy comprising cyclophosphamide 1,000 mg m-2 i.v., doxorubicin 50 mg m-2 i.v., vincristine 1.4 mg m-2 i.v. and prednisolone 40 mg orally for 5 days, given 3 weekly for four cycles prior to undergoing loco-regional radiotherapy. All patients completed treatment as planned with no major acute toxicity from either chemotherapy or radiotherapy. Subsequently 52 patients with stage T4 breast cancer were randomised in a phase III trial to receive either radiotherapy alone (RT) or this chemotherapy and radiotherapy (CHOP + RT). A significantly higher complete response rate was achieved in the CHOP + RT treatment arm (P = 0.03). However a larger proportion of the RT arm achieved loco-regional control after salvage treatment for relapse such that 50% of the RT arm and 57% of the CHOP + RT arm had no evidence of loco-regional disease at the time of last follow-up or death. There was no statistical difference in time to distant relapse or overall survival. Analysis of the pilot study showed results comparable to the trial CHOP + RT arm. This trial suggests that this cytotoxic therapy used in conjunction with radiotherapy has only marginal value in improving prognosis in locally advanced breast cancer.
Collapse
Affiliation(s)
- A Rodger
- Department of Clinical Oncology, Western General Hospital, Edinburgh, UK
| | | | | | | | | | | |
Collapse
|
24
|
Abstract
Locally advanced breast cancer is a heterogenous group including both operable and inoperable lesions. Local surgery or radiation alone produces poor survival rates, indicating micrometastases at diagnosis. Systemic chemotherapy as part of multimodality regimens has increased the length and rate of disease-free survival.
Collapse
Affiliation(s)
- S M Swain
- Division of Medical Oncology, Vincent T. Lombardi Cancer Research Center, Georgetown University Medical Center, Washington, DC
| |
Collapse
|
25
|
Abstract
The definition of locally advanced breast cancer includes patients with large tumors, extensive regional lymph node involvement, or direct involvement of the skin or underlying chest wall. Most of these patients have very poor survival with standard treatment modalities, and over the past 20 years combined modality therapy has been used to improve local and systemic control. There is limited information suggesting that patients with operable locally advanced breast cancer have an improved survival if treated with surgery (or radiation therapy) followed by systemic chemotherapy, as compared with patients treated with local modalities alone. Uncontrolled trials strongly suggest that patients with any stage of locally advanced breast cancer achieve high response rates after induction chemotherapy. Most of these patients can be rendered disease free after combined modality therapy, and their disease-free and overall survival rates appear to be improved when compared with historical controls. These results are most impressive for patients with inflammatory breast cancer, a disease previously found to be uniformly lethal when treated with local modalities of therapy alone. More recently, 30% to 50% of these patients were alive and disease free 5 years after diagnosis, and a substantial percentage were in the same condition 10 years later. Combined modality therapies are the most appropriate approach to patients with locally advanced breast cancer. Much additional research must be done to improve the results of these therapies and maximize the survival of patients with locally advanced breast cancer.
Collapse
Affiliation(s)
- G N Hortobagyi
- Department of Medical Oncology, University of Texas, M.D. Anderson Cancer Center, Houston 77030
| |
Collapse
|
26
|
Abstract
Five-year results are reported on 27 patients with locally advanced breast cancer treated by intraarterial induction chemotherapy followed by radiotherapy and/or surgery with subsequent adjuvant chemotherapy. The cyclic infusion chemotherapy regimen was given over 3 to 6 weeks using Adriamycin (doxorubicin), 5-fluorouracil (5-FU), vincristine, and methotrexate in daily rotation. Regional and systemic side effects were minimal and temporary except in two patients in whom some skin discoloration has remained. Local tumor control and 5-year cures depended on two important factors: whether follow-up mastectomy was used after initial local tumor regression; and whether the carcinoma was classified as "inflammatory" with pathologic evidence of tumor invasion of dermal lymphatics. Of 16 patients with noninflammatory carcinoma treated by chemotherapy, radiotherapy, and mastectomy local tumor eradication was achieved in 15 and 5-year apparent cure in 11. Of six patients with noninflammatory carcinoma treated with chemotherapy and radiotherapy but no mastectomy 5-year local control was achieved in only three and 5-year apparent cure in three. Of five patients with pathologic inflammatory carcinoma local tumor control was achieved in only one and only this one patient has been a 5-year survivor apparently tumor-free.
Collapse
Affiliation(s)
- F O Stephens
- Department of Surgery, University of Sydney, NSW, Australia
| |
Collapse
|
27
|
Dorr FA, Bader J, Friedman MA. Locally advanced breast cancer current status and future directions. Int J Radiat Oncol Biol Phys 1989; 16:775-84. [PMID: 2646263 DOI: 10.1016/0360-3016(89)90497-5] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Patients described as having locally advanced breast cancer comprise a heterogeneous group of patients with variable clinical presentations. Systematic evaluation of patients with these presentations has been limited, with much of our current understanding based on retrospective reviews. Prospective pilot studies have demonstrated the feasibility of multimodality therapy. However, there have been few well-conducted randomized trials in this setting. Comparison of results among studies is made difficult by the varying eligibility criteria and the way in which the data are reported. The use of common and consistent definitions of operable and inoperable disease is necessary for a more uniform understanding of the therapeutic interventions necessary for a given patient within this broad category of Stage III or locally advanced breast cancer. There are a variety of opportunities for clinical research activities in this group of patients including tests of hormonal recruitment or synchronization, high dose chemotherapy requiring autologous bone marrow transplantation, perioperative or preoperative chemotherapy, and alternating chemotherapy with short course radiotherapy. The integration of clinical information with biological characteristics of the tumor such as cytokinetics, oncogene amplification, and hormone receptors will be an important and necessary focus of future investigation in this disease.
Collapse
Affiliation(s)
- F A Dorr
- Clinical Investigations Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892
| | | | | |
Collapse
|
28
|
Campbell IR, Green JA, Errington RD, Leinster SJ, Myint S, Warenius HM. Sequential chemotherapy, surgery and radiotherapy in locally advanced breast cancer. Clin Radiol 1988; 39:442-5. [PMID: 3180658 DOI: 10.1016/s0009-9260(88)80300-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Thirty-seven patients with locally advanced breast cancer, 86% of whom had skin involvement, were treated with three to six cycles of vincristine 1.4 mg m-2, doxorubicin 40 mg m-2 and cyclophosphamide 600 mg m-2. A complete response rate of 19%, and overall response rate of 61% were achieved. Fourteen patients had received a trial of hormone therapy, but no patient had been given prior cytotoxic chemotherapy or radiation therapy. In no case was chemotherapy discontinued on account of toxicity. In patients with partial remission where gross disease more than 3 cm remained, mastectomy (10 patients) or local excision (five patients), was carried out increasing the complete remission rate to 49%. Thirty-two patients then received 45 Gy in 24 days to the breast and regional lymphatics with a further 12 Gy boost to the tumour site. The overall response rate achieved was 86% of the 37 patients, with a total, complete response rate of 76%. The median time to relapse in the 28 complete responders was 17 months. Local palliation, defined as absence of pain, ulceration or an enlarging mass was achieved in 92% of the total number of patients, and the projected local palliation rate at 2 years by life table analysis was 60%. Only 50% of the 10 N3 patients were alive at 1 year, compared to 93% of the 27 N0-N2 patients (P less than 0.05). The overall survival in the entire group at 2 years was 50%. This is an effective and tolerable combined modality approach for the control of local disease in a subgroup of breast cancer patients with complex management problems.
Collapse
Affiliation(s)
- I R Campbell
- Cancer Research Campaign Department of Radiation Oncology, Clatterbridge Hospital, Merseyside
| | | | | | | | | | | |
Collapse
|
29
|
Abstract
This study of compliance was performed to determine whether a medically indigent population with breast carcinoma that has been neglected is an appropriate group for inclusion in an aggressive combined treatment program. After incisional biopsy, 28 locally advanced breast cancer (LABC) patients received two cycles of cytoxan, Adriamycin, 5-Fluorouracil, and tamoxifen (CAFT) followed by a simple mastectomy and level I axillary dissection. After surgery, patients received four additional cycles of CAFT alternating with three cycles of 15 Gy to the chest wall and regional lymphatics. Compliance was defined as overall compliance, the percentage of patients completing the protocol as described; and appointment compliance, the ratio between treatments or appointments attended versus those scheduled. Overall compliance was 75% (21 of 28 patients). The total number of appointments scheduled was 1054 (mean, 37 +/- 2), and the total attended was 965 (mean, 34 +/- 3), giving an appointment compliance rate of 91.7%. Compliance did not vary significantly with age, marital status, nationality, the presence of complications, or delay to diagnosis. Compliance did decrease significantly with time. There was 100% overall compliance at 2 months, 82% at 6 months, and 75% at 1 year. We conclude that although our patients had neglected their disease and were medically indigent, they were highly motivated patients once in therapy. This suggests that complex treatment regimens are feasible as well as effective for the treatment of LABC.
Collapse
Affiliation(s)
- D Berger
- Department of Surgery, State University of New York Health Science Center, Brooklyn
| | | | | | | |
Collapse
|
30
|
Brun B, Otmezguine Y, Feuilhade F, Julien M, Lebourgeois JP, Calitchi E, Roucayrol AM, Ganem G, Huart J, Pierquin B. Treatment of inflammatory breast cancer with combination chemotherapy and mastectomy versus breast conservation. Cancer 1988; 61:1096-103. [PMID: 3342369 DOI: 10.1002/1097-0142(19880315)61:6<1096::aid-cncr2820610608>3.0.co;2-y] [Citation(s) in RCA: 56] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Twenty-six consecutive patients with nonmetastatic inflammatory breast cancer (IBC), were treated in a single institution using the same protocol, and all were followed for at least 48 months. The first phase of treatment consisted of two monthly cycles of combination chemotherapy with Adriamycin (Adria Laboratories, Columbus, OH), vincristine, cyclophosphamide and 5-fluorouracil. Local treatment was then undertaken using in all cases a cobalt 60 beam to deliver 45 Gy to the entire mammary gland and lymph-draining areas. Local treatment was completed either by mastectomy, or by conservation of the breast and interstitial irradiation of the primary tumor site. Chemotherapy was resumed after completion of local treatment for a total of 6 cycles. Metastatic disease occurred in 19 of 26 patients from 8 to 55 months; five patients are alive and free of disease from 48 to 81 months. Failure to control local disease or local recurrences was noted in two of ten patients undergoing mastectomy, and in seven of 13 patients with conservation of the breast. While this difference is not statistically significant we concluded that methods of breast conservation which limit the high dose volume to the tumor site do not assure local control in IBC. The median disease-free survival and overall survival of 12 and 31 months, respectively, are not satisfactory. Better systemic treatment is needed.
Collapse
Affiliation(s)
- B Brun
- Department of Cancer, Henri Mondor Hospital, Creteil, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Abstract
Case histories of 103 patients with locally advanced (stage III) breast cancer have been reviewed. Ninety of the patients were judged operable. The median follow-up time was 52 months. The 5-year survival rate for the whole group was 54%. The 5-year relapse-free survival rates for the pN0, pN1 and pN2-3 were 91, 50 and 19% respectively and the 5-year survival rates for the groups were 86, 53 and 30% respectively. These results underline the heterogeneity and the very different prognoses for the different subgroups in stage III breast cancer patients. A reevaluation of the staging system is therefore suggested.
Collapse
Affiliation(s)
- G Baldursson
- Department of Oncology, University Hospital, Lund, Sweden
| |
Collapse
|
32
|
Conte PF, Alama A, Bertelli G, Canavese G, Carnino F, Catturich A, Di Marco E, Gardin G, Jacomuzzi A, Monzeglio C. Chemotherapy with estrogenic recruitment and surgery in locally advanced breast cancer: clinical and cytokinetic results. Int J Cancer 1987; 40:490-4. [PMID: 3666987 DOI: 10.1002/ijc.2910400410] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Thirty-nine patients with locally advanced breast cancer (T3b-4, N1-3 or inflammatory carcinoma) received 3 cycles of induction chemotherapy with estrogenic recruitment before surgery. The therapeutic regimen consisted of diethylstilbestrol (DES) orally on days 1-3, 5-Fluorouracil + Doxorubicin + Cyclophosphamide on day 4 q 21 days (DES-FAC). After surgery 6 additional cycles of chemotherapy (3 DES-FAC alternating with 3 DES-CMF with Methotrexate + F and C as in FAC) were administered. The objective response rate was 71.8% with 15.4% CR, and 56.4% PR; after surgery 36/39 (92.3%) patients were rendered disease-free. So far, 13 of 26 patients in stage IIIb have relapsed (9 of 13 with inflammatory carcinomas). Three-year survival and progression-free survival are 60% and 53.5%, respectively. Twenty-three of the 39 patients were subjected to serial tumor biopsies during the first DES-FAC regimen to allow for tumor-cell kinetic studies during DES and chemotherapy. A significant estrogenic recruitment occurred in 16 patients (69.6%), irrespective of estrogen-receptor status. At surgery, 3-4 weeks after induction chemotherapy, tumor proliferative activity was significantly depressed in comparison to basal values. These results indicate that breast cancer cells can be recruited in vivo with DES and that chemotherapy following estrogenic stimulation is effective and feasible with acceptable toxicity.
Collapse
Affiliation(s)
- P F Conte
- Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Suhrland LG. An Overview of Contemporary Management of Breast Carcinoma. Obstet Gynecol Clin North Am 1987. [DOI: 10.1016/s0889-8545(21)00091-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
34
|
Casper ES, Guidera CA, Bosl GJ, Hakes TB, Kaufman RJ, Shurgot B, Kinne DW. Combined modality treatment of locally advanced breast cancer: adjuvant combination chemotherapy with and without doxorubicin. Breast Cancer Res Treat 1987; 9:39-44. [PMID: 3593990 DOI: 10.1007/bf01806692] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Forty-one women with non-metastatic but locally advanced breast cancer were treated by modified radical or radical mastectomy, and were then randomized to receive one of two adjuvant chemotherapy regimens. Regimen A consisted of 6 months of cyclophosphamide, adriamycin, and fluorouracil (CAF) followed by 6 months of cyclophosphamide, methotrexate, fluorouracil, vincristine, and prednisone (CMFVP). Regimen B was 12 months of CMFVP. Patients were stratified for estrogen-receptor status, and all patients with a positive estrogen receptor value received tamoxifen 20 mg bid in addition to the chemotherapy. Eight of 21 patients randomized to Regimen A are alive and free of disease, whereas only 1 of 20 patients on Regimen B is well. A trend toward improved disease-free survival favoring Regimen A was observed (P = .05), although a significant difference in overall survival has not been demonstrated. Our findings support the continued study of adriamycin-containing regimens in the adjuvant setting and in combined modality therapy of locally advanced breast cancer.
Collapse
|
35
|
Sherry MM, Johnson DH, Page DL, Greco FA, Hainsworth JD. Inflammatory carcinoma of the breast. Clinical review and summary of the Vanderbilt experience with multi-modality therapy. Am J Med 1985; 79:355-64. [PMID: 4036986 DOI: 10.1016/0002-9343(85)90314-6] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Inflammatory breast cancer is a distinct clinicopathologic entity that accounts for 1 percent of all cases of breast cancer. The diagnosis should be strongly suspected on the basis of the distinctive clinical findings, which include edema of the breast, inflammation, wheals, and a typical reddish-purple color of the overlying skin. Pathologic examination usually shows infiltration of the dermal lymphatics with carcinoma. Evidence of distant metastatic spread is more frequent than with other types of breast cancer and is seen in approximately 30 percent of patients. The five-year disease-free survival rate is less than 5 percent when local therapy alone (mastectomy and/or local radiotherapy) is used. The addition of combination chemotherapy to high-dose local radiotherapy has improved the five-year survival rate to approximately 30 percent. The potential for long-term survival is limited to the subgroup of patients with only local-regional disease at the time of diagnosis. Patients with inflammatory breast cancer should be treated with combined-modality therapy using combination chemotherapy and high-dose radiotherapy to the breast, since this approach is potentially curative. The fatalism formerly associated with this diagnosis is no longer warranted, particularly in patients with local-regional disease. Failure to employ intensive combined-modality treatment will deny some patients a chance for long-term survival.
Collapse
|
36
|
Carbone PP. The present dilemma of adjuvant chemotherapy: acceptance and risks versus benefits. Recent Results Cancer Res 1984; 96:218-23. [PMID: 6396777 DOI: 10.1007/978-3-642-82357-2_28] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
The acceptance of ACT has been very rapid since 1974 although earlier studies by Nissen-Meyer and the NSABP in the 1960's originally suggested the effectiveness of modest short-term chemotherapy [16, 17]. The current practice is to administer combination chemotherapy for at least 6 months in all node-positive women. The survival benefits are clearly established only for women who are premenopausal and who have fewer than three positive nodes. Trials in other groups of patients are highly suggestive but have lacked some or all of the rigorous standards of the randomized clinical trial. The reasons for this widespread acceptance of ACT are not clear, but both patients and physicians are able to appreciate the concepts and bear the costs in terms of money as well as toxicity. The risks of ACT are mainly short term and reversible. Long-term consequences are not so readily apparent as yet. The benefits of improved survival will only be appreciated as more time passes, either through the long-term analyses of the current trials or the overwhelming success of a new strategy. Then all the past arguments about one therapy or another will become irrelevant. At that point this new miracle treatment will be so good that none will ask whether CMF is better than surgery alone. In essence, the old standard has become the control.
Collapse
|